Pharmacy Times: How AI, machine learning can benefit pharmaceutical development, research
Pharmacy Times highlighted a presentation from the University of Cincinnati's Shawn Xiong discussing the potential for artificial intelligence (AI) and machine learning to bolster pharmaceutical development and research.
Xiong, PhD, assistant professor at UC's James L. Winkle College of Pharmacy, presented the American Pharmacists Association (APhA)-Academy of Pharmaceutical Research and Science Keynote at the 2024 APhA Meeting and Exposition March 22.
In the pharmaceutical industry, Xiong said the top three use cases for AI are predictive maintenance, quality inspection and assurance and manufacturing process optimization. In clinical practice, Xiong said early detection and personalized treatment are particularly exciting areas of potential.
“This is not only about identifying the disease itself,” Xiong said. “It’s also about providing insights into the unique situations of the patient so that we can make personalized treatments for the patient, especially considering the concept of patient-centered care.”
While the potential is encouraging, Xiong noted there are still limitations and concerns, including nuances of medical language and privacy and security concerns with patient data. As these issues are addressed, however, Xiong said AI and machine learning could significantly improve the future of pharmacy.
“AI and machine learning can help automate the medication filling process, improving accuracy and also saving time,” Xiong said. “The AI can help check and double-check errors in the medication orders, and they can help us identify errors and reduce errors so that patients are getting what they need and how they need it.”
Read the Pharmacy Times article.
Featured image courtesy of Adobe Stock.
Related Stories
Student leaders find community in the University Honors Program
March 9, 2026
The Student Leader Roundtable (SLRT), a semester-long experience available to undergraduate students in the University Honors Program (UHP), offers campus leaders a vital space for discussion, connection and skill development.
Phase 1 trial tests probiotic treatment for radiation side effects in the gut
March 9, 2026
The University of Cincinnati Cancer Center’s Bailey Nelson, MD, has been awarded a $50,000 pilot grant from the Cancer Center to open a Phase 1 trial testing if a probiotic supplement can reduce gastrointestinal symptoms for patients undergoing whole pelvis radiotherapy.
Is uACR the key to cardiovascular and kidney disease prevention?
March 8, 2026
As a precision biomarker, the urinary albumin-to-creatinine ratio (uACR) can guide physicians toward personalized, patient-centered prevention and treatment of both cardiovascular disease (CVD) and chronic kidney disease (CKD), according to new data published in the Journal of Internal Medicine.